Skip to content
10-K

Annual Report

Dermata Therapeutics, Inc. DRMA DRMAW

0001493152-26-012992

← back to feed
Filed
Mar 26, 2026 12:00 AM ET
Period of report
Restated figures. One or more values in this filing restate previously reported amounts.

On SEC.gov

Financials in this filing

Metric Period Value
Shares Outstanding FY 2025 · Mar 25, 2026 4.02M sh
Shares Diluted FY 2025 · Dec 31, 2025 926.19K sh
Shares Diluted restated FY 2025 · Dec 31, 2024 152.97K sh
Operating Cash Flow FY 2025 · Dec 31, 2025 −$7.76M
Operating Cash Flow FY 2025 · Dec 31, 2024 −$11.16M
Cash And Equivalents FY 2025 · Dec 31, 2025 $7.52M
Cash And Equivalents FY 2025 · Dec 31, 2024 $3.16M
Stockholders Equity FY 2025 · Dec 31, 2025 $6.22M
Stockholders Equity FY 2025 · Dec 31, 2024 $1.56M
Stockholders Equity FY 2025 · Dec 31, 2023 $6.36M
Total Liabilities FY 2025 · Dec 31, 2025 $1.64M
Total Liabilities FY 2025 · Dec 31, 2024 $1.97M
Total Assets FY 2025 · Dec 31, 2025 $7.86M
Total Assets FY 2025 · Dec 31, 2024 $3.53M
Eps Diluted FY 2025 · Dec 31, 2025 −$8.16
Eps Diluted restated FY 2025 · Dec 31, 2024 −$80.32
Eps Basic FY 2025 · Dec 31, 2025 −$8.16
Eps Basic restated FY 2025 · Dec 31, 2024 −$80.32
Sga Expense FY 2025 · Dec 31, 2025 $4.84M
Sga Expense FY 2025 · Dec 31, 2024 $4.31M
Rd Expense FY 2025 · Dec 31, 2025 $2.93M
Rd Expense FY 2025 · Dec 31, 2024 $8.2M
Net Income FY 2025 · Dec 31, 2025 −$7.56M
Net Income FY 2025 · Dec 31, 2024 −$12.29M
Operating Income FY 2025 · Dec 31, 2025 −$7.77M
Operating Income FY 2025 · Dec 31, 2024 −$12.51M